EMA Authorised: Brineura (cerliponase alfa) — BioMarin International Limited

View source ↗

Summary

EMA confirms authorisation of Brineura (cerliponase alfa) for Neuronal Ceroid-Lipofuscinoses, designated as an orphan medicine with accelerated assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuronal Ceroid Lipofuscinoses

Drugs mentioned

• BRINEURA (cerliponase alfa)

Snippet

Status: Authorised. Therapeutic area: Neuronal Ceroid-Lipofuscinoses. MAH: BioMarin International Limited. Decision date: 11/12/2023. Orphan medicine. Accelerated assessment